CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40831024.
- Also identified by DOI 10.1002/cncr.70056 and PMC identifier 12365368.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although no survival benefit over standard therapies has been established, the combination of sotorasib plus panitumumab recently received full US Food and Drug Administration approval for use in advanced colorectal cancer. The authors highlight key concerns with the CodeBreaK 300 trial design, conduct, and reporting, arguing that excitement for precision medicines must be matched by methodological rigor and transparent reporting.